共 50 条
Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey
被引:48
|作者:
Potpara, Tatjana S.
[1
,2
]
Dan, Gheorghe-Andrei
[3
]
Trendafilova, Elina
[4
]
Goda, Artan
[5
]
Kusljugic, Zumreta
[6
]
Manola, Sime
[7
]
Music, Ljilja
[8
]
Musetescu, Rodica
[9
]
Badila, Elisabeta
[10
]
Mitic, Gorana
[11
]
Paparisto, Vilma
[5
]
Dimitrova, Elena S.
[4
]
Polovina, Marija M.
[1
,2
]
Petranov, Stanislav L.
[12
]
Djergo, Hortensia
[5
]
Loncar, Daniela
[6
]
Bijedic, Amira
[6
]
Brusich, Sandro
[13
]
Lip, Gregory Y. H.
[1
,2
,14
]
机构:
[1] Univ Belgrade, Sch Med, Belgrade, Serbia
[2] Clin Ctr Serbia, Cardiol Clin, Belgrade, Serbia
[3] Med Univ Carol Davila, Colentina Univ Hosp, Bucharest, Romania
[4] Natl Heart Hosp, Sofia, Bulgaria
[5] Univ Hosp Ctr Mother Theresa, Clin Cardiol, Tirana, Albania
[6] Clin Internal Dis, Dept Cardiol, Tuzla, Bosnia & Herceg
[7] Clin Hosp Ctr Sestre Milosrdnice, Zagreb, Croatia
[8] Univ Clin Ctr Podgorica, Podgorica, Montenegro
[9] Cty Emergency Hosp, Ctr Cardiol, Craiova, Romania
[10] Med Univ Carol Davila, Dept Internal Med, Emergency Clin Hosp, Bucharest, Romania
[11] Clin Ctr Vojvodina, Novi Sad, Serbia
[12] Multiprofile Hosp Act Treatment, Burgas, Bulgaria
[13] Clin Hosp Ctr Rijeka, Rijeka, Croatia
[14] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
来源:
关键词:
EUROPEAN COUNTRIES;
FOLLOW-UP;
MANAGEMENT;
ANTICOAGULATION;
RISK;
ASPIRIN;
PROGNOSIS;
MORTALITY;
WARFARIN;
REGISTRY;
D O I:
10.1038/srep20432
中图分类号:
O [数理科学和化学];
P [天文学、地球科学];
Q [生物科学];
N [自然科学总论];
学科分类号:
07 ;
0710 ;
09 ;
摘要:
Data on the management of atrial fibrillation (AF) in the Balkan Region are limited. The Serbian AF Association (SAFA) prospectively investigated contemporary 'real-world' AF management in clinical practice in Albania, Bosnia&Herzegovina, Bulgaria, Croatia, Montenegro, Romania and Serbia through a 14-week (December 2014-February 2015) prospective, multicentre survey of consecutive AF patients. We report the results pertinent to stroke prevention strategies. Of 2712 enrolled patients, 2663 (98.2%) with complete data were included in this analysis (mean age 69.1 +/- 10.9 years, female 44.6%). Overall, 1960 patients (73.6%) received oral anticoagulants (OAC) and 762 (28.6%) received antiplatelet drugs. Of patients given OAC, 17.2% received non-vitamin K antagonist oral anticoagulants (NOACs). CHA(2)DS(2)-VASc score was not significantly associated with OAC use. Of the 'truly low-risk' patients (CHA(2)DS(2)-VASc = 0 [males], or 1 [females]) 56.5% received OAC. Time in Therapeutic Range (TTR) was available in only 18.7% of patients (mean TTR: 49.5% +/- 22.3%). Age = 80 years, prior myocardial infarction and paroxysmal AF were independent predictors of OAC non-use. Our survey shows a relatively high overall use of OAC in AF patients, but with low quality of vitamin K antagonist therapy and insufficient adherence to AF guidelines. Additional efforts are needed to improve AF-related thromboprophylaxis in clinical practice in the Balkan Region.
引用
收藏
页数:10
相关论文